1396037-29-8

Basic information

• Product Name: 2-methylthio-(E,E)-4,6-bis(4'-methoxymethoxy-3'-N,N-dimethylaminostyryl)pyrimidine
• Synonyms: 2-methylthio-(E,E)-4,6-bis(4'-methoxymethoxy-3'-N,N-dimethylaminostyryl)pyrimidine
• CAS NO: 1396037-29-8
• Molecular Weight: 536.695
• Mol File: 1396037-29-8.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 2-methylthio-(E,E)-4,6-bis(4'-methoxymethoxy-3'-N,N-dimethylaminostyryl)pyrimidine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-methylthio-(E,E)-4,6-bis(4'-methoxymethoxy-3'-N,N-dimethylaminostyryl)pyrimidine(1396037-29-8)
• EPA Substance Registry System: 2-methylthio-(E,E)-4,6-bis(4'-methoxymethoxy-3'-N,N-dimethylaminostyryl)pyrimidine(1396037-29-8)

Safety Data

• Hazardous Substances Data: 1396037-29-8(Hazardous Substances Data)

Upstream product

• 123-54-6 acetylacetone 
• 1396038-77-9 N,N-3-(dimethylamino)-4-(methoxymethyl)benzyl alcohol 
• 1396038-68-8 N,N-3-(dimethylamino)-4-(methoxymethyl)benzoic acid methyl ester 
• 14001-64-0 4,6-dimethyl-2-methylsulfanyl-pyrimidine 
• 145600-72-2 N,N-3-(dimethylamino)-4-(methoxymethyl)benzaldehyde 

Downstream Products

• 1236355-48-8 2-methylthio-(E,E)-4,6-bis-(4'-hydroxy-3'-N,N-dimethylaminostyryl)pyrimidine 

Relevant articles and documents

Small molecules that protect against β-amyloid-induced cytotoxicity by inhibiting aggregation of β-amyloid

Aggregated β-amyloid (Aβ) plays crucial roles in Alzheimer's disease (AD) pathogenesis, therefore blockade of Aβ aggregation is considered as a potential therapeutic target. We designed and synthesized small molecules to reduce Aβ-induced cytotoxicity by inhibiting Aβ aggregation. The small molecules were screened via ThT, MTT, and cell-based cytotoxicity assay (Aβ burden assay). Selected compounds 1c, 1d, 1e, and 1f were then investigated by evaluating their effects on cognitive impairment of acute AD mice model. Learning and memory dysfunction by injection of Aβ(1-42) was recovered by administration of these molecules. Especially, 1d showed the best recovery activity in Y-maze task, object recognition task, and passive avoidance task with dose dependent manner. These results suggest that 1d has high potential as a therapeutic agent for AD.